Exosome therapeutics developer Codiak BioSciences, exploiting technology developed by researchers at the universities of Gothenburg and Texas, is eyeing up to $86.3m in an IPO.
Codiak BioSciences, a US-based exosome therapeutics developer, has filed to raise up to $86.3m in an initial public offering.
Founded in 2015, Codiak is developing exosome therapeutics to treat a range of conditions, including cancer, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders and rare diseases.
The company’s therapeutics are created by engineering exosomes, extracellular vesicles that are produced by nearly all cells in the human body and which can change the biological function of cells.
The approach is based on research conducted at the VentureLabs unit of Flagship Pioneering, by Jan Lotvall, chairman of Krefting Research Centre at University of Gothenburg, and by Raghu Kalluri, chairman and professor of the Department of Cancer Biology and director of the Metastasis Research Center at University of Texas MD Anderson Cancer Center.
Proceeds from the IPO will be used to conduct studies and a phase 1/2 clinical…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
